Next Phase Newsletter

A venture capital firm based in China, with additional offices in Silicon Valley and Hong Kong. has approximately USD 1 billion AUM and has raised 4 funds to date. The firm’s most recent fund was raised in 2011 with a size of $350 million. The firm invests primarily in the internet, wireless, green technology and semiconductors sectors, but has a dedicated team focused on healthcare opportunities. For healthcare, the firm mainly focuses on series A rounds. The firm can invest globally, but is only looking for opportunities with a China angle (substantial operations/markets in China). The firm is actively seeking new investment opportunities.

Currently the firm is focused on healthcare IT opportunities. The firm looks for early stage, consumer-facing products with a special interest in artificial intelligence in healthcare. The firm is indication agnostic but is interested in products that address a large unmet medical need in China.

The firm is only interested in opportunities with a China angle. Depending on the opportunity, the firm can lead the investment or co-invest in a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A member-managed seed stage angel capital fund specializes in seed investment in early stage businesses with valuation of up to $2.5M and seeking funding of less than $2M to reach profitability. The firm often co-invests with other angel investors. Typical investments range from $75-150K, but larger allocations are possible in syndication with local angel groups. The firm is seeking opportunities in the Research Triangle Park area and expects to make 2-3 new investments per year.

The firm considers a wide range of market sectors, with an emphasis on technology. In life sciences, the firm is interested in medical devices that do not require regulatory approval. The firm prefers companies from post-proof-of-concept to pre-revenue stage. The firm typically avoids biotechnology, pharmaceuticals, and health software.

The firm is looking for competent and experienced management teams with flexibility and coachability in working with investors. The firm supervises the companies by directly taking a board seat or through co-investors on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A major global pharma firm with over $10 billion in annual sales is seeking innovative drugs and noel therapeutic approaches to supplement the firm’s pipeline.  The firm focuses on prescription products in cardiology, women’s healthcare, oncology, hematology and ophthalmology. The firm also has a radiology business which markets diagnostic imaging equipment together with the necessary contrast agents.

Within the Life Science space the firm is interested in pre-clinical stage small molecules and biologics as well as imaging agents, biomarkers and companion diagnostics targeting a number of various indications. In the oncology space the firm is interested in assets targeting solid tumors at all development stages starting from compounds with proof of efficacy in animals. Mechanisms of action of particular interest include Oncogenic Signaling, Antibody-Drug Conjugates, Thorium Conjugates and Immuno-Oncology. The firm is also very interested in women’s health and is willing to look very early in this indication area, requiring just a validated target. Within gynecology, the firm is interested in Endometriosis, Uterine Fibroids and Polycystic Ovary Syndrome. The firm also has interest in Cardiology mainly in diseases/conditions that are treated by specialists. These include Heart Diseases, Vascular Diseases, Kidney Diseases, Lung Diseases, Hemostatic Disorders and Acute Organ Disorders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that was founded in 2005 based in the Netherlands is managing two funds. The firm typically makes equity investments into life science companies at preclinical and clinical stages. The investment size is up to €2.5 million. The firm generally makes 1-3 allocations per year. The firm focuses on companies that are based in the Netherlands and Belgium.

The firm is currently looking for new investment opportunities in Therapeutics, Diagnostics and Medical Devices spaces. The firm is very opportunistic in terms of subsectors and it is interested in Medical Products in the broad sense. The firm also has no restrictions in terms of indications; however, it is most interested in companies with potential for real benefit and/or potential to save healthcare costs. The firm also consider orphan drugs if the business case is good. Historically, the firm was active in medical technology companies developing imaging, surgical instruments and single use devices. The firm was also active in therapeutics and diagnostics companies specializing in drug delivery, biomarker and vaccines.

The firm focuses on investments in private companies and it will consider pre-revenue companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. The firm is current investing from its newest US$100 million and RMB 1 billion funds closed in 2016. Typical equity allocations range from US$2-6 million in an early stage company, while the firm can participate from pre-series A to pre-IPO financing rounds. The firm is currently seeking opportunities from China, US, and EU.

The firm currently focuses on medical devices and IVD tools in late clinical development or early commercial stage with high entry battier. The firm focuses on diseases with large market potential such as oncology and cardiovascular conditions.

The firm is looking for experienced management teams. The firm typically syndicates with other investors and takes 10%-20% minority stake in a financing round. Board representation is often required. The firm prefers China-based companies, Chinese-owned foreign businesses, or products with a China-angle; however this is not a requirement. The firm can provide its expertise to help with registration, distribution, M&A, and formation of joint venture and strategic partnership in the country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in California invests in multiple areas of technology: mobile, health, e-commerce, enterprise, education, fintech, and connected devices. The firm is currently investing out of a $200M fund that allocates $500K – $10M per company. The firm is stage agnostic and invests in seed, Series A, and growth rounds, and can both lead and co-invest. The firm invests globally, but the companies must have ties to the U.S (either offices or customers).

The firm is interested in innovative medical devices, genomics, healthcare IT, wearables, and consumer technology. The firm is not interested in technology that will require FDA approval and has a preference for those that at least have initial traction with pilot customers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the US Midwest makes growth-stage, equity investments in a variety of sectors, including the life sciences, typically in the $2M-$10M range. The firm prefers to lead rounds, but will also syndicate deals. The firm’s first fund closed late in 2015, and is targeting between 3 and 5 investments per year, focusing on the Midwestern United States. However, this includes all states except for those in the North East and those on the West Coast.

Within the Life Science space, the firm is primarily interested in data-driven, connected medical devices and diagnostics as well as any technology that improves drug adherence (mobile apps, devices, etc.). The firm has deep domain experience in IT and is therefore very interested in healthcare IT, such as enterprise software solutions. In addition, life science tools are also an area of interest. The firm is open to all sectors within the life sciences, with the exception of therapeutics, given the product is already FDA approved or is exempt from regulatory approval.

The firm prefers to work with experienced management teams and serial entrepreneurs, however the firm is open to working with first-time entrepreneurs. The firm prefers to lead rounds and requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com